<DOC>
	<DOCNO>NCT00234507</DOCNO>
	<brief_summary>The purpose study compare effectiveness 3 dos Dysport® placebo assess functional disability blepharospasm .</brief_summary>
	<brief_title>Study Single Administration 3 Doses Dysport® Treatment Benign Essential Blepharospasm</brief_title>
	<detailed_description />
	<mesh_term>Blepharospasm</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>patient confirm diagnosis bilateral benign essential blepharospasm , symptom least 6 month prior baseline visit naïve patient botulinum toxin type A treatment , patient receive single treatment botulinum toxin type A , demonstrate satisfactory response , investigator 's opinion , last 2 injection botulinum toxin type A minimum 12 week since last injection injection full dosage indicate patient minimum score 8 BDS patient either neurolepticinduced blepharospasm , isolated levator dysfunction apraxia previous surgical , chemical thermal myectomy neurectomy condition intramuscular injection contraindicate ophthalmolgical infection myasthenia gravis disorder neuromuscular junction prescription antispastic , muscle relaxant medication affect neuromuscular junction transmission , medication dose choice medication constant last 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2006</verification_date>
</DOC>